Clinical trials: Cardiovascular Condition
Atrial Fibrillation, Atrial Fibrillation, Persistent
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and…
- Conditions
- Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia
- Trial name
- RESOLVE-AF (NCT05883631)
- Testing
- Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation, Electrographic Flow (EGF) mapping (no ablation)
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 400 people
- Sponsor
- Cortex
Stroke
Neurorehabilitation of the Hand
Stroke is the number one cause of adult disability in the world. Due to the neurological damage from stroke, a vast majority of individuals suffer from hand function disability (~70%).
- Trial name
- NCT05549375
- Testing
- MyHand System Hand Rehabilitation
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- IRegained Inc.
Thrombosis, Venous
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of…
- Trial name
- NCT00911157
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 24 sites in Japan
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe Acute Lower Back Pain
Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.
- Trial name
- NCT05096494
- Testing
- SP-103
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- Scilex Pharmaceuticals, Inc.
Relapse/Refractory Multiple Myeloma
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study was to evaluate the efficacy and safety of panobinostat in combination with bortezomib and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT02290431
- Testing
- LBH589 (panobinostat), bortezomib, dexamethasone
- Where
- 20 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina
Primary: To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients Secondary: To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients.
- Trial name
- RAFEHELP (NCT00507845)
- Testing
- Ramipril-Felodipine
- Where
- Argentina
- Volunteers
- 271 people
- Sponsor
- Sanofi
Multiple Myeloma
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.
- Trial name
- NCT03660072
- Testing
- Non-Interventional
- Where
- South Korea
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation
WAVECREST Post Market Clinical Follow-Up (PMCF) Study
The WAVECREST PMCF Study is a prospective, non-randomized, multicenter study to confirm safety and performance of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System in the current medical practice setting in…
- Trial name
- NCT03204695
- Testing
- Percutaneous LAA Closure, Anticoagulation or Clopidogrel
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- Coherex Medical
Pulmonary Hypertension, Left Heart Disease
A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)
This study will assess multiple doses of MK-8892 administered to participants with pulmonary hypertension "out of proportion" (PHOOP) and heart failure with reduced left ventricular ejection fraction (rEF).
- Trial name
- NCT02078557
- Testing
- MK-8892
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Hypotension
Accuracy of Non-Invasive Blood Pressure Measurement in Adults
The purpose of this study is to compare the accuracy of the Sotera ViSi, an investigational device, to auscultation (measurement with a cuff) in determining systolic and diastolic blood pressure (BP) in adult subjects.
- Trial name
- NIBP (NCT01183741)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sotera Wireless, Inc.
Hypercholesterolemia, Coronary Disease
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
- Trial name
- NCT00092612
- Testing
- MK0653, ezetimibe
- Volunteers
- 372 people
- Sponsor
- Organon and Co
Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy
Non-invasive Prenatal Diagnostic Validation Study
The primary purpose of this study is to collect maternal blood samples from pregnant women to develop a non-invasive prenatal diagnostic test based on fetal DNA isolated from maternal blood.
- Conditions
- Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations
- Trial name
- NIPD (NCT01574781)
- Testing
- Blood draw, Cheek swab/Saliva Sampling
- Where
- United States
- Volunteers
- 1,781 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Coronary Artery Disease, High Bleeding Risk Patients
ULTRA LONG: BioFreedom Ultra
The goal of this Prospective, multi-center, open-label single-arm study is to Assess the Safety and Effectiveness of additional sizes of the BioFreedom Ultra CoCr Biolimus A9 coated coronary stent system in Patients at high risk…
- Trial name
- NCT05643430
- Testing
- BioFreedom Ultra
- Where
- 9 sites in France, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Biosensors Europe SA
Hypertension, Dyslipidemias
A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348
A clinical trial to compare the pharmacokinetics and tolerability of CKD-348
- Trial name
- CKD-348 (NCT04258865)
- Testing
- CKD-348 F1, CKD-348 F2, CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan 300 mg Tablets under fed conditions.
- Trial name
- NCT01712100
- Testing
- Irbesartan, Avapro
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Heart Failure
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level.
- Trial name
- ESCAPE-SHF (NCT00923156)
- Testing
- aliskiren, ramipril
- Where
- 16 sites in Germany, Poland and 1 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure
The main aim of this study is to check the safety of TAK-536. This study will take place in Japan. At the first visit, the study doctor will check if each child can take part.
- Trial name
- NCT04668157
- Testing
- TAK-536
- Where
- 19 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Takeda
Heart Failure
Heart Failure IDentification in a High Risk Cardiovascular OutpatiEnt Population (HIDE)
This is a pilot, multicenter, real-world, single-visit, low risk, phase IV interventional study to efficiently identify new cases of heart failure (HF) Stage C in subjects who are at risk of cardiovascular (CV) disease in…
- Trial name
- HIDE (NCT04143919)
- Testing
- NYHA assessment, Serum NT-proBNP concentration, Transthoracic Ecocardiogram
- Where
- 5 sites in Dominican Republic, El Salvador and 1 more
- Volunteers
- 317 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
The purpose of this study is to compare if the combination of valsartan 320 mg/lisinopril 20 mg versus the monotherapies of lisinopril 40 mg or valsartan 320 mg will result in a greater decrease of urinary albumin excretion…
- Trial name
- NCT00171067
- Testing
- valsartan, lisinopril
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 134 people
- Sponsor
- Novartis
Multiple Myeloma, Neoplasms
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
The purpose of this study is to see how long lenalidomide therapy can maintain or improve the disease response obtained after induction therapy that does not include lenalidomide, pomalidomide or thalidomide; and consequently…
- Conditions
- Multiple Myeloma, Neoplasms, Plasma Cells, Paraproteinemias
- Trial name
- NCT02155634
- Testing
- Lenalidomide
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.